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METHOTREXATE (MTX) has for many
years been used in the maintenance phase
of therapy for acute lymphoblastic leu-
kaemia (ALL), but the dose, route of
administration and timing still vary be-
tween protocols. It is now possible, with
accurate immunoassay techniques, to mea-
sure and compare serum MTX concentra-
tions in children receiving treatment with
various maintenance regimens. The oral
and the i.m. routes are currently used in
the Medical Research Council United
Kingdom Acute Lymphoblastic Leukae-
mia (UKALL) trials and the i.v. route has
been used in a number of American
studies (Simone, 1974). MTX concentra-
tions after different routes have been
previously studied in adults (Freeman-
Narrod et al., 1975; Calvert et al., 1977)
but the results are not necessarily applic-
able to children, owing to differences in
age, disease and the doses used. In the
study reported here serum MTX profiles
were compared after a standard dose was
given to the same patients after each of 3
routes, oral, i.m. and i.v.
Six children were studied. All were
being managed according to UKALL
protocols; 3 received oral MTX routinely,
1 received i.m. therapy and 2 had com-
pleted maintenance therapy 2 and 36
months before this study. MTX (15 mg/
m2) was first given by the oral route with
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water after an overnight fast. Blood
samples were taken from an indwelling
venous cannula at 0, 20, 40, 60 min and
1-5, 2, 3 and 4 h after administration. On a
subsequent occasion, usually within a
month, the same dose was given as an i.m.
injection into the buttock (parenteral
solution, 25 mg/ml). Finally, MTX was
given as an i.v. bolus, diluted to 5 ml with
normal saline and injected over 30 sec.
Blood samples were taken at 0, 10, 20, 40,
60 min and 2, 3 and 4 h after the i.v. dose.
Specimens of serum were analysed by
enzyme-linked immunoassay (EMIT MTX
Assay, Silva, Maidenhead).
Serum profiles were compared in rela-
tion to the peak MTX concentration, its
timing and the drug levels up to 4 h. The
paired t-test was used for statistical
analysis.
Results are shown in the Figure. In all
cases the oral route produced lower peak
concentrations than the i.m. route (P<
0.001) and levels were generally lower
throughout the period studied. MTX was
also more rapidly absorbed from the i.m.
site, with significantly earlier peak con-
centrations (P< 0 02). Although the initial
concentrations at 10 and 20 min were very
high with the i.v. dose (10-5-10-4M), the
rapid decline over the first 3 h produced no
significant difference between oral and
i.v. after 2 h. Moreover, in Cases 1-3
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FIGURE.-Serum methotrexate profiles in 6 children after oral (D- ), i.m. (0) and i.v.
of a standard MTX dose (15 mg/M2).
(6)
(A) administration
MTX concentrations were higher with the other routes. Because of the rapid absorp-
oral route. tion of the i.m. dose there was no signifi-
In most cases the i.m. route produced cant difference between i.m. and i.v. con-
more sustained concentrations, with high- centrations at 1 h. In Case 5 the lower
er levels at 3 and 4 h than either of the concentration at 4 h with the i.m. route
SERUM
MTX
({M )
1.0
(1)
SERUM
MTX
(M )
1.0
301C. R. PINKERTON, S. G. WELSHMAN AND J. M. BRIDGES
appeared to be due to poorer i.m. absorp-
tion than in other cases, rather than
particularly sustained levels with the i.v.
route. In most cases, the rapid decline in
concentration with the i.v. dose produced
lower levels beyond 2 h than with the i.m.
dose.
Although most drugs are better ab-
sorbed from an injection site, this is not
necessarily the case, and some have been
reported to reach higher, more consistent
concentrations after oral than i.m. admin-
istration. (Curry, 1977; Scott & Hawks-
worth, 1981). With MTX, the i.v. route
produced by far the highest peak concen-
trations but these were brief, and rapid
distribution and excretion caused an early
decline. Serum levels greater than 10-5M
may be of value in relation to resistant
blast cells in which the concentrations
achieved with the oral and i.m. routes
may be inadequate to overcome limita-
tions due to poor intracellular transport or
high dihydrofolate reductase binding re-
quirements (Bertino et al., 1962; Harrap,
et al., 1971). This might explain the
improved response in some resistant cases
using infusion schedules (Djerassi et al.,
1967). In most patients, however, such
high concentrations are probably unneces-
sary, and routine i.v. therapy may be
related to increased neurological toxicity
(Aur et al., 1978). The rapid fall in serum
MTX after an i.v. dose has been previ-
ously described in adults with psoriasis
(Noble et al., 1975) and a variety of solid
tumours (Freeman-Narrod et al., 1975).
Quite marked interpatient variation in the
rate of distribution after an i.v. dose was
evident in this study, and was similar to
that reported in adults (Huffman et al.,
1973). This may have been due to differ-
ences in tissue- or serum protein-binding
associated with very high drug concentra-
tions. By contrast, the patterns of serum
levels with the i.m. route were generally
very consistent, and in all cases peaks were
at least twice as high as those withthe oral
route. The slower decline in concentrations
after an i.m. dose may have been due to
continued uptake of drug from the injec-
tion site. This has been described in adults
(Freeman-Narrod et al., 1975; Calvert et
al., 1977) and furthermore it has been
suggested that this is associated with a
better therapeutic response in some solid
tumours (Freeman-Narrod et al., 1975).
In the interpretation of serum profiles
after different routes of administration, it
is important to consider the possibility
that assay cross-reaction occurs betweeii
MTX and its metabolites. 4-Amino-4-
deoxyNl0-methylpteroic acid (APA), for
example, may result from bacterial action
in the gut, and consequently influence oral
profiles. This is, however, more important
with high-dose schedules and prolonged
studies, where metabolite concentrations
are likely to be high.
Previous studies in children with ALL
have demonstrated poor oral absorption in
some cases. This is usually characterized
by a slow rate of absorption and peak
concentrations less than 0 5 pM (Kierney
et al., 1979; Pinkerton, 1980). As such poor
absorption may contribute to therapeutic
failure in such cases, might not the parent-
eral route be of value in these patients? It
is clear from these data that the i.v. route
has no particular advantages, but com-
pared with the oral the i.m. route produces
higher and earlier peak concentrations and
a greater degree ofabsorption, as reflected
in the higher concentrations up to 4 h.
Another possible advantage might be
increased patient compliance, as therapy
would be given under supervision. This
route is, however, both inconvenient and
uncomfortable. To date there is no
adequate clinical information to justify its
routine use, but it may have a role where
oral absorption is demonstrated to be poor.
A limitation shared by all 3 routes was
the brevity for which serum concentra-
tions were maintained above 10-7M. Stud-
ies in vitro have indicated that the
maximum cytotoxicity is likely to occur
where the extracellular drug concentration
is maintained at , 10-6M (Goldman,
1977). As such concentrations are achieved
for only a few hours the therapeutic
effectiveness of current regimens may not
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be optimal. Further studies are required to
determine whether alternative schedules
involving higher doses, possibly divided
over 24 h, might produce advantageous
serum profiles.
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